Inhibition of the MAP kinase activity suppresses estrogen-induced breast tumor growth both in vitro and in vivo

International Journal of Oncology

Volumn 30, Issue 4, 2007, Pages 971-975

  Reddy, Kaladhar B ^a   Glaros, Selina ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; CI 1040; Estrogen; MAPK; Tamoxifen

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2-(2-CHLORO-4-IODOPHENYLAMINO)-N-CYCLOPROPYLMETHOXY-3,4-DIFLUOROBENZAMIDE; ANTIESTROGEN; BENZAMIDE DERIVATIVE; ESTRADIOL; ESTROGEN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST TUMOR; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HUMAN; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BENZAMIDES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; HUMANS; MAP KINASE KINASE KINASES; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 34247890106     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.4.971     Document Type: Article

References (36)

1. Buzdar AU and Hortobagyi G: Update on endocrine therapy for breast cancer. Clin Cancer Res 4: 527-534, 1998. (Pubitemid 28193549)
2. Huang HJ, Neven P, Drijkoningen M, et al: Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related. Breast Cancer Res Treat 91: 81-87, 2005. (Pubitemid 40684941)
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717, 2005.
4. Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F and Reddy KB: MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Oncogene 21: 4000-4008, 2002. (Pubitemid 34679241)
5. Nicholson RI and Gee JM: Oestrogen and growth factor crosstalk and endocrine insensitivity and acquired resistance in breast cancer. Br J Cancer 82: 501-513, 2000.
6. Kato S, Endoh H, Masuhiro Y, et al: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270: 1491-1494, 1995.
7. Kelly MJ and Levin ER: Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol Metab 12: 152-156, 2001. (Pubitemid 33713555)
8. Canagarajah BJ, Khokhlatchev A, Cobb MH and Goldsmith EJ: Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell 90: 859-869, 1997.
9. Keshamouni VG, Mattingly RR and Reddy KB: Mechanism of 17-beta-estradiol-induced Erk1/2 activation in breast cancer cells. A role for HER2 and PKC-delta. J Biol Chem 277: 22558-22565, 2002.
10. Bunone G, Briand PA, Miksicek RJ and Picard D: Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 15: 2174-2183, 1996.
11. Coutts AS and Murphy LC: Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Res 58: 4071-4074, 1998.
12. Maemura M, Iino Y, Koibuchi Y, Yokoe T and Morishita Y: Mitogen-activated protein kinase cascade in breast cancer. Oncology 57 (Suppl 2): 37-44, 1999.
13. Mueller H, Flury N, Eppenberger-Castori S, Kueng W, David F and Eppenberger U: Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer 89: 384-388, 2000.
14. Sivaraman VS, Wang H, Nuovo GJ and Malbon CC: Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 99: 1478-1483, 1997.
15. Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD and Miles DW: Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 79: 1220-1226, 1999.
16. Nabha SM, Glaros S, Hong M, et al: Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells. Oncogene 24: 3166-3176, 2005.
17. Nicholson RI, McClelland RA, Finlay P, et al: Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 29A: 1018-1023, 1993.
18. Rocha RL, Hilsenbeck SG, Jackson JG, et al: Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res 3: 103-109, 1997.
19. Reddy KB, Mangold GL, Tandon AK, et al: Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Cancer Res 52: 3636-3641, 1992.
20. Cowley S, Paterson H, Kemp P and Marshall CJ: Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77: 841-852, 1994.
21. Mansour SJ, Matten WT, Hermann AS, et al: Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265: 966-970, 1994.
22. Sebolt-Leopold JS, Dudley DT, Herrera R, et al: Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5: 810-816, 1999.
23. Pages G, Lenormand P, L'Allemain G, Chambard JC, Meloche S and Pouyssegur J: Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc Natl Acad Sci USA 90: 8319-8323, 1993.
24. Castoria G, Barone MV, Di Domenico M, et al: Non-transcriptional action of oestradiol and progestin triggers DNA synthesis. EMBO J 18: 2500-2510, 1999.
25. Kaulsay KK, Mertani HC, Tornell J, Morel G, Lee KO and Lobie PE: Autocrine stimulation of human mammary carcinoma cell proliferation by human growth hormone. Exp Cell Res 250: 35-50, 1999.
26. Reddy KB, Yee D, Hilsenbeck SG, Coffey RJ and Osborne CK: Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expression. Cell Growth Differ 5: 1275-1282, 1994. (Pubitemid 24381515)
27. Osborne CK: Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 51: 227-238, 1998. (Pubitemid 29054556)
28. Fisher B, Costantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320: 479-484, 1989. (Pubitemid 19062522)
29. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388, 1998.
30. Clarke R, Leonessa F, Welch JN and Skaar TC: Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 53: 25-71, 2001. (Pubitemid 32173107)
31. Rinehart J, Adjei AA, Lorusso PM, et al: Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22: 4456-4462, 2004.
32. Burton A: What went wrong with Iressa? Lancet Oncol 3: 708, 2002.
33. Kurokawa H, Lenferink AE, Simpson JF, et al: Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 60: 5887-5894, 2000.
34. Witters LM, Kumar R, Chinchilli VM and Lipton A: Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res Treat 42: 1-5, 1997. (Pubitemid 27056722)
35. Murphy L, Cherlet T, Adeyinka A, Niu Y, Snell L and Watson P: Phospho-serine-118 estrogen receptor-alpha detection in human breast tumors in vivo. Clin Cancer Res 10: 1354-1359, 2004. (Pubitemid 38365228)
36. Murphy LC, Niu Y, Snell L and Watson P: Phospho-serine-118 estrogen receptor-alpha expression is associated with better disease outcome in women treated with tamoxifen. Clin Cancer Res 10: 5902-5906, 2004. (Pubitemid 39180972)